Evidence analysisOctober 30, 2026Evidence

PSUSA/00002152/202602

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.

Evidence Dossier: Periodic Safety Update Report Single Assessment on Nicorandil

What is established

The European Medicines Agency (EMA) published a periodic safety update report single assessment (PSUSA) regarding the active substance nicorandil on October 30, 2026. The PSUSA is part of ongoing pharmacovigilance efforts intended to monitor the safety profile of medicines authorised in the European Union after they have entered the market.

Nicorandil is the substance under review, with the procedure number PSUSA/00002152/202602. This report consolidates safety data reported by marketing authorisation holders (MAHs) at defined intervals following the medicine’s initial authorisation, aiming to detect, assess, understand, and prevent suspected adverse reactions to the drug.

What the source claims

The EMA presents the PSUSA as a comprehensive evaluation of safety data related to nicorandil. It implies that the review process includes national authorisation statuses and a full assessment of data compiled from various regions of the EU. The PSUSA aims to determine whether the benefit-risk balance remains favourable for nicorandil or if regulatory actions are necessary to protect public health.

The document notably cites a consolidation of safety information in a structured format and reports on any new signals or risks related to nicorandil identified since previous evaluations.

What may be missing from the usual framing

  • Detailed Data Transparency: The summary does not provide access to full datasets or detailed descriptions of adverse events, which limits public insight into the scope and severity of reported safety concerns.
  • Context of Use: There is no elaboration on the specific patient populations or clinical contexts where nicorandil’s risks might differ, such as comorbidities or polypharmacy scenarios.
  • Comparative Safety: The assessment does not discuss how nicorandil’s evolving safety profile compares with alternative treatments available in the EU or globally, which could inform prescriber choices.

Competing evidence or uncertainty

Evidence is insufficient to fully understand any emerging risks or safety signals from the nicorandil PSUSA alone because the publicly available summary does not disclose detailed findings, data analyses, or conclusions drawn by the EMA panel. Other sources of evidence, such as independent clinical studies, post-marketing surveillance data beyond the EU, or patient-reported outcomes, are not referenced, making it difficult to evaluate competing views or uncertainties comprehensively.

Additionally, the influence of commercial interests from marketing authorisation holders in reporting and interpreting safety data represents a potential source of bias, though the EMA’s regulatory role is designed to mitigate such risks.

Why it matters

Nicorandil is used to treat angina and related cardiovascular conditions. Continuous safety monitoring is critical because adverse drug reactions can impact morbidity and mortality in users. Updated safety assessments like this PSUSA inform healthcare professionals, regulatory authorities, and patients about any changes needed in drug usage, warnings, or contraindications to ensure safe treatment.

Regulatory decisions stemming from such assessments can lead to label changes, restrictions, or, in rare cases, withdrawal from the market—actions with significant implications for patient care and pharmaceutical markets.

What to verify next

  • Review the full PSUSA document provided by the EMA to understand detailed safety findings and regulatory conclusions for nicorandil.
  • Check for any updates on regulatory actions or communications from national health authorities regarding nicorandil following this assessment.
  • Investigate independent studies or pharmacovigilance databases for corroborating or divergent data on nicorandil’s safety signals.
  • Monitor patient and healthcare provider reports or expert analyses that can shed light on real-world experiences with nicorandil, especially in varying clinical contexts.

Readers interested in a comprehensive understanding should consult the original EMA source and related medical literature for contextualized information.

Source & verification

Primary source: What's new · October 30, 2026

Read the original source

FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.

Continue reading

Burkina Faso Targets Critics in Exile

Accountability in Burkina Faso: Evidence Dossier on Judicial Repression of Critics Abroad What is established Since a military coup in September 2022, the ruling…